Here's Why Progenics Pharmaceuticals, Inc. Lost Ground Today
Despite upbeat recent developments, shares of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) fell 15.3% during Wednesday's session. The biotech reported solid progress with clinical-stage candidates, but a steep drop in Relistor revenue weighed on the stock.
An injectable form of Progenics' Relistor for the treatment of opioid-induced constipation has been available since 2008. Investors expected a tablet version approved last July to lead to significantly higher sales and are punishing the stock because the revenue hasn't materialized.
Image source: Getty Images.
Source: Fool.com
